ReviewClinics in chest medicine2016
The Microbiome in Cystic Fibrosis.
Review in Clinics in chest medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04176328 (An Open-label, Dose-escalation Study to Evaluate the Pharmacokinetics of Inhaled Teicoplanin in Cystic Fibrosis Patients), which is not on this map. Cited by 83 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
An Open-label, Dose-escalation Study to Evaluate the Pharmacokinetics of Inhaled Teicoplanin in Cystic Fibrosis Patients
Who cites it
83 citing papers in PubMed.
- The role of small intestinal bacterial overgrowth in cystic fibrosis: a randomized case-controlled clinical trial with rifaximin.Journal of gastroenterology · 2019Trial
- A Different Microbiome Gene Repertoire in the Airways of Cystic Fibrosis Patients with Severe Lung Disease.International journal of molecular sciences · 2017Trial
- Mitochondria Meet the Lung Microbiome: A Bidirectional Dialogue in Inflammation and Respiratory Diseases.Biomedicines · 2026Review
- An ode to the 16S rRNA gene: its history, importance, caveats and future in microbiome research.Microbial genomics · 2026Review
- Review
- Article
- Airway Microbiome in Children with Cystic Fibrosis: A Review of Microbial Shifts and Therapeutic Impacts.Medicina (Kaunas, Lithuania) · 2025Review
- Article
- Comparative microbiome analysis in cystic fibrosis and non-cystic fibrosis bronchiectasis.Respiratory research · 2024Article
- Comparison of culture and PCR-DGGE methods to evaluate the airways of cystic fibrosis patients and determination of their antibiotic resistance profile.Iranian journal of microbiology · 2023Article
- Stability Considerations for Bacteriophages in Liquid Formulations Designed for Nebulization.Cells · 2023Review
- Enrichment of human nasopharyngeal bacteriome with bacteria from dust after short-term exposure to indoor environment: a pilot study.BMC microbiology · 2023Article
- Lung-gut axis of microbiome alterations following co-exposure to ultrafine carbon black and ozone.Particle and fibre toxicology · 2023Article
- Loss of CFTR function in macrophages alters the cell transcriptional program and delays lung resolution of inflammation.Frontiers in immunology · 2023Article
- Phage therapy for pulmonary infections: lessons from clinical experiences and key considerations.European respiratory review : an official journal of the European Respiratory Society · 2022Review
- Antibiotics Drive Expansion of Rare Pathogens in a Chronic Infection Microbiome Model.mSphere · 2022Article
- The effect of probiotic administration on metabolomics and glucose metabolism in CF patients.Pediatric pulmonology · 2022Article
- Review
- The Effect of CFTR Modulators on Airway Infection in Cystic Fibrosis.International journal of molecular sciences · 2022Review
- Nontypeable Haemophilus influenzae Infection Impedes Pseudomonas aeruginosa Colonization and Persistence in Mouse Respiratory Tract.Infection and immunity · 2022Article
23 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Observations from studies during the last decade have changed the conventional view of cystic fibrosis (CF) microbiology, which has traditionally focused on a limited suite of opportunistic bacterial pathogens. It is now appreciated that CF airways typically harbor complex microbial communities, and that changes in the structure and activity of these communities have a bearing on patient clinical condition and lung disease progression. Recent studies of gut microbiota also suggest that disordered bacterial ecology of the CF gastrointestinal tract is associated with pulmonary outcomes. These new insights may alter future clinical management of CF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.